Biotechnology company Pandorum Technologies has raised $18 million in Series B funding, led by Protons Corporate.
Other investors in the round include Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family, among others.
The company plans to use the funds to expand its clinical programs, scale up manufacturing, and enter new markets in the U.S., Japan, and the Middle East. Part of the investment will also be used to strengthen regulatory and clinical operations.
“Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core, “said Dr. Tuhin Bhowmick, Co-Founder and CEO of Pandorum. “Our approach treats tissue health, disease, and degeneration as a navigational challenge within an information-constrained biological landscape,” added Dr. Tuhin. “This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision- to heal fast and age slow.”“Congratulations to our team for this achievement. Regenerative medicine, particularly for corneal blindness, is a global necessity that knows no borders,” said co-founder Arun Chandru.
Founded by Tuhin Bhowmick and Arun Chandru, Bengaluru-based Pandorum Technologies works in regenerative medicine and biotechnology. The company develops exosome-based therapies designed to support tissue regeneration and operates in both India and the United States.
Pandorum follows a global manufacturing model. It partners with AGC Biologics for production in the U.S. and Europe, and with Nucelion Therapeutics, a subsidiary of Bharat Biotech, to supply products across the Asia-Pacific region.
In addition to its current operations, the company is also planning to build new partnerships in the Middle East to expand its global reach.
Read More- Safqah Capital raises $15.2 million seed round led by Shorooq
